Pfizer has declared that following encouraging preliminary findings in an early to mid-stage investigation, its combination vaccine candidates targeting Covid and the flu will advance to a final-stage trial in the upcoming months.
This brings the multinational pharmaceutical company and its German partner BioNTech one step closer to obtaining possible regulatory approval for a flu and Covid combo shot. Pfizer stated earlier this year that it intended to release a vaccine against the two respiratory viruses by 2024 at the latest.
Combination doses, according to Pfizer and other vaccine manufacturers like Moderna and Novavax, will make it easier for patients to protect themselves against respiratory infections, which usually peak around the same time of year.
“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices,” Annaliesa Anderson, Pfizer’s head of vaccine research and development, said in a release.
During a call with investors earlier this month, Pfizer CEO Albert Bourla expressed his belief that combination vaccines' simplicity will "unlock a significant potential by improving the vaccination rates."
The United States' COVID-19 vaccination rates were dismal last year, and they may remain so this year.
Adults between the ages of 18 and 64 participated in the experiment to evaluate the safety, tolerability, and efficacy of Pfizer's combination vaccination candidates. Additionally, the research contrasted the combination vaccinations with a licenced influenza vaccine and Pfizer's bivalent Covid shot, which targets the original strain of the virus as well as the omicron variants BA.4 and BA.5.
Pfizer said that the "lead" formulations of their combination vaccination shown strong immune responses against strains of Covid, influenza A, and influenza B. The combination vaccination candidates' safety profiles matched those of the Covid vaccine produced by the business.
Additionally, Pfizer and BioNTech are working on a vaccine that targets RSV in addition to Covid. Moderna and Novavax are creating their own combination shots in the interim.
(Source:www.cnbc.com)
This brings the multinational pharmaceutical company and its German partner BioNTech one step closer to obtaining possible regulatory approval for a flu and Covid combo shot. Pfizer stated earlier this year that it intended to release a vaccine against the two respiratory viruses by 2024 at the latest.
Combination doses, according to Pfizer and other vaccine manufacturers like Moderna and Novavax, will make it easier for patients to protect themselves against respiratory infections, which usually peak around the same time of year.
“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices,” Annaliesa Anderson, Pfizer’s head of vaccine research and development, said in a release.
During a call with investors earlier this month, Pfizer CEO Albert Bourla expressed his belief that combination vaccines' simplicity will "unlock a significant potential by improving the vaccination rates."
The United States' COVID-19 vaccination rates were dismal last year, and they may remain so this year.
Adults between the ages of 18 and 64 participated in the experiment to evaluate the safety, tolerability, and efficacy of Pfizer's combination vaccination candidates. Additionally, the research contrasted the combination vaccinations with a licenced influenza vaccine and Pfizer's bivalent Covid shot, which targets the original strain of the virus as well as the omicron variants BA.4 and BA.5.
Pfizer said that the "lead" formulations of their combination vaccination shown strong immune responses against strains of Covid, influenza A, and influenza B. The combination vaccination candidates' safety profiles matched those of the Covid vaccine produced by the business.
Additionally, Pfizer and BioNTech are working on a vaccine that targets RSV in addition to Covid. Moderna and Novavax are creating their own combination shots in the interim.
(Source:www.cnbc.com)
